Efficacy and safety of TACE combined with tyrosine kinase inhibitors and camrelizumab for unresectable hepatocellular carcinoma: A systematic review and meta-analysis

被引:0
|
作者
Yu, Jiahui [1 ]
Yan, Duan [1 ]
Wei, Song [1 ]
Yang, Linfeng [1 ]
Yi, Pengsheng [1 ]
机构
[1] North Sichuan Med Coll, Affiliated Hosp, Dept Hepatobiliary Pancreas 2, 1 Maoyuan South Rd, Nanchong 637000, Sichuan, Peoples R China
关键词
transcatheter arterial chemoembolization; tyrosine kinase inhibitors; camrelizumab; hepatocellular carcinoma; meta-analysis; TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION; TRANSARTERIAL CHEMOEMBOLIZATION; DOUBLE-BLIND; MULTICENTER; APATINIB; THERAPY; ANTIBODIES; LENVATINIB; TRIALS;
D O I
10.3892/ol.2024.14534
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Transcatheter arterial chemoembolization (TACE) combined with tyrosine kinase inhibitors (TKIs) and camrelizumab (collectively: T-T-C) is a novel treatment strategy for unresectable hepatocellular carcinoma (HCC). The present systematic review and meta-analysis aimed to evaluate the efficacy and safety of T-T-C compared with TACE combined with TKIs only (T-T) in the treatment of patients with unresectable HCC. A systematic literature search was conducted on T-T and T-T-C using PubMed, Embase and the Cochrane Library. Data regarding the clinical outcome, including overall survival (OS), progression-free survival (PFS), tumor response and adverse events (AEs), were independently extracted and analyzed by two researchers using standardized protocols. In total, 7 cohort studies, including 1,798 patients (T-T-C, 838; T-T, 960), were included in the meta-analysis. The results of the present study demonstrated that the T-T-C group had significantly prolonged OS [hazard ratio (HR), 0.38; 95% confidence interval (CI), 0.29-0.50; I2=61.5%; P=0.016)] and PFS (HR, 0.37; 95% CI, 0.30-0.46; I2=44.5%; P=0.109), and showed significantly higher objective response rates [risk ratio (RR), 0.82; 95% CI, 0.69-0.96; I2=25.1%; P=0.237)] and slightly higher disease control rates without a significant difference (RR, 0.96; 95% CI, 0.89-1.03; I2=0.0%; P=0.969). In addition, grade 3/4 AEs were more common in the T-T group, including hypertension (RR, 1.15; 95% CI, 0.85-1.56), vomiting or nausea (RR, 0.88; 95% CI, 0.44-1.76) and pain (RR, 0.74; 95% CI, 0.45-1.21); however, these results were not statistically significant. In conclusion, compared with T-T combination therapy, T-T-C demonstrated a notable advantage in terms of OS, PFS, ORR and DCR in patients with unresectable HCC. For manageable AEs, although the results were not statistically significant, the incidence of AEs in the T-T group was higher than that in the T-T-C group in terms of event probability.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Efficacy and safety of camrelizumab combined with TACE for hepatocellular carcinoma: a systematic review and meta-analysis
    Xian, F.
    Song, X. -W.
    Bie, J.
    Zhao, C. -X.
    Zhang, G. -J.
    Xu, G. -H.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2024, 28 (02) : 687 - 701
  • [2] Safety and efficacy of transarterial chemoembolization combined with tyrosine kinase inhibitors and camrelizumab in the treatment of patients with advanced unresectable hepatocellular carcinoma
    Li, Jinpeng
    Jia, Yuntao
    Han, Huihui
    Lin, Yanyan
    Song, Jinlong
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [3] Safety and efficacy of transarterial chemoembolization combined with tyrosine kinase inhibitors and camrelizumab in the treatment of patients with advanced unresectable hepatocellular carcinoma
    Li, Jinpeng
    Kong, Mingxin
    Yu, Guangji
    Wang, Song
    Shi, Zhaozhang
    Han, Huihui
    Lin, Yanyan
    Shi, Jutian
    Song, Jinlong
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [4] Efficacy and safety of drug-eluting bead transarterial chemoembolization (DEB-TACE) combined with tyrosine kinase inhibitors (TKIs) in patients with unresectable hepatocellular carcinoma (uHCC): A systematic review and meta-analysis
    Ji, Jun
    Zhang, Zhihong
    Hou, Ziqi
    Qiu, Guoteng
    Mi, Shizheng
    Jin, Zhaoxing
    Huang, Jiwei
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2024, 48 (04)
  • [5] Transarterial chemoembolization (TACE) plus tyrosine kinase inhibitors versus TACE in patients with hepatocellular carcinoma: a systematic review and meta-analysis
    Duan, Ruihua
    Gong, Fen
    Wang, Yan
    Huang, Caixia
    Wu, Jiaming
    Hu, Leihao
    Liu, Min
    Qiu, Shijun
    Lu, Liming
    Lin, Yisheng
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2023, 21 (01)
  • [6] Transarterial chemoembolization (TACE) plus tyrosine kinase inhibitors versus TACE in patients with hepatocellular carcinoma: a systematic review and meta-analysis
    Ruihua Duan
    Fen Gong
    Yan Wang
    Caixia Huang
    Jiaming Wu
    Leihao Hu
    Min Liu
    Shijun Qiu
    Liming Lu
    Yisheng Lin
    World Journal of Surgical Oncology, 21
  • [7] The safety and efficacy of TACE combined with HAIC, PD-1 inhibitors, and tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: a retrospective study
    Huang, Zhongjing
    Wu, Ziyi
    Zhang, Lidong
    Yan, Likun
    Jiang, Hai
    Ai, Junhua
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [8] Efficacy and safety of hepatic arterial infusion chemotherapy combined with immune checkpoint inhibitors and tyrosine kinase inhibitors in advanced hepatocellular carcinoma: A systematic review and meta-analysis
    Li, Zixiong
    Xu, Yanping
    Qu, Wenshu
    Liu, Ping
    Zhu, Yan
    Li, Hui
    Guo, Ying
    Liu, Xiufeng
    ONCOLOGY LETTERS, 2023, 26 (06)
  • [9] Efficacy of Transarterial Chemoembolization Combined With Camrelizumab in the Treatment of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
    Tashrifwala, Fatema Ali Asgar
    Karmani, Vikash Kumar
    Haider, Ihtisham
    Syeda, Amna Zubia
    Noorani, Amber
    Mustafa, Muhammad Saqlain
    Dave, Tirth
    Hafeez, Hassan
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (11)
  • [10] Efficacy of transarterial therapy combined with first-line tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: a network meta-analysis
    Hu, Lingbo
    Lin, Jiangying
    Shi, Xingpeng
    Wang, Aidong
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2023, 21 (01)